Zheng Quan Shi Bao Wang·2025-11-12 08:40Group 1 - The cell immunotherapy concept has seen a rise of 2.20%, making it the top-performing sector, with 43 stocks increasing in value [1][2] - Notable gainers include Kaineng Health, which hit a 20% limit up, and other companies like Nanjing Xinbai, Jimin Health, and Zhongyuan Qihe also reached their daily limit up [1] - The top gainers in percentage terms include Sanyuan Gene (up 12.45%), Guanhao Biological (up 7.47%), and Chengda Pharmaceutical (up 6.34%) [1] Group 2 - The cell immunotherapy sector attracted a net inflow of 1.465 billion yuan, with 38 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflow [2] - Zhongyuan Qihe led the net inflow with 220 million yuan, followed by Jimin Health (209 million yuan), Hengrui Pharmaceutical (192 million yuan), and Nanjing Xinbai (176 million yuan) [2][3] - The net inflow ratios for Nanjing Xinbai, Jimin Health, and Zhongyuan Qihe were 34.82%, 26.18%, and 25.74% respectively, indicating strong investor interest [3]